VICO Vicore Pharma Holding AB (publ)

STO · SE · Healthcare · Biotechnology · vicorepharma.com

8.890SEK-4.61%Mkt Cap: 239.50M $P/E: —Today

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap239.50M USD

Enterprise Value164.35M USD

Revenue (TTM)382.03K USD

Gross Profit365.10K USD

Net Income (TTM)-45.67M USD

Revenue/Share0.01 SEK

Last Price8.890 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees46

CountrySE

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-4.85

PEG—

EV/EBITDA—

EV/Revenue430.19

P/S657.22

P/B3.06

EPS (TTM)-1.91

EPS (Forward)-1.92

52W Range

8.6203% of range18.24

52W High18.24 SEK

52W Low8.620 SEK

Profitability

Gross Margin100.00%

Oper. Margin-6762.49%

EBITDA Margin0.00%

Profit Margin-12509.14%

ROE-43.59%

ROA-39.18%

Growth

Revenue Growth26.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF-35.94M USD

CapEx (TTM)—

FCF Margin-7085.19%

FCF Yield-11.30%

Net Debt-86.63M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio12.68

Quick Ratio12.50

Book Value/Sh3.05 SEK

Cash/Share3.22 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 SEK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.1 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)26.92 SEK

Upside (mean)+202.8%

Target Range15.00 SEK – 38.00 SEK

15.00+202.8% to mean38.00

# Analysts6

Ownership

Shares Out.281.64M

Float198.58M

Insiders12.74%

Institutions59.01%

Technical

SMA 5010.69 (-16.9%)

SMA 20010.91 (-18.5%)

Beta0.12

S&P 52W Chg14.58%

Avg Vol (30d)837.88K

Avg Vol (10d)801.58K

Technical Indicators

RSI (14)32.3

MACD-0.4178

MACD Signal-0.3587

MACD Hist.-0.0591

BB Upper11.50 SEK

BB Middle10.17 SEK

BB Lower8.834 SEK

BB Width26.24%

ATR (14)0.3781 SEK

Vol Ratio (20d)1.02x